(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Blueprint Medicines Corporation
MacroGenics
Fondazione IRCCS Policlinico San Matteo di Pavia
Cogent Biosciences, Inc.
Telios Pharma, Inc.